Jupiter Topco LLC Takes $66.24 Million Position in Alumis Inc. $ALMS

Jupiter Topco LLC acquired a new stake in Alumis Inc. (NASDAQ:ALMS) during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,355,122 shares of the company’s stock, valued at approximately $66,238,000. Jupiter Topco LLC owned about 1.85% of Alumis at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new position in shares of Alumis in the 2nd quarter valued at $231,259,000. MPM Bioimpact LLC acquired a new stake in Alumis in the fourth quarter valued at about $23,443,000. Janus Henderson Group PLC bought a new position in Alumis in the first quarter valued at about $46,790,000. Orbimed Advisors LLC bought a new position in Alumis in the second quarter valued at about $5,779,000. Finally, Woodline Partners LP raised its stake in Alumis by 809.7% during the third quarter. Woodline Partners LP now owns 1,751,150 shares of the company’s stock worth $6,987,000 after acquiring an additional 1,558,660 shares in the last quarter.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on ALMS shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Alumis in a report on Tuesday, July 7th. Chardan Capital upped their price objective on shares of Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, May 19th. Morgan Stanley reiterated an “overweight” rating and set a $39.00 price objective on shares of Alumis in a research report on Friday, May 15th. Wall Street Zen raised shares of Alumis from a “strong sell” rating to a “hold” rating in a research note on Sunday, August 23rd. Finally, HC Wainwright restated a “neutral” rating and issued a $25.00 target price on shares of Alumis in a research report on Friday, August 14th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $40.30.

Alumis Trading Down 1.7%

Alumis stock opened at $23.21 on Friday. The stock has a 50-day moving average price of $26.57 and a two-hundred day moving average price of $25.11. Alumis Inc. has a 12 month low of $3.76 and a 12 month high of $31.35. The company has a market capitalization of $3.00 billion, a PE ratio of -6.01 and a beta of -0.69.

Alumis (NASDAQ:ALMS) last released its quarterly earnings results on Thursday, August 13th. The company reported ($1.11) earnings per share for the quarter, missing the consensus estimate of ($0.77) by ($0.34). The firm had revenue of $1.66 million for the quarter, compared to the consensus estimate of $3.65 million. Alumis had a negative return on equity of 93.15% and a negative net margin of 5,933.46%. As a group, analysts predict that Alumis Inc. will post -2.95 earnings per share for the current fiscal year.

Insider Activity

In other news, insider Roy C. Hardiman sold 2,692 shares of the firm’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total transaction of $70,988.04. Following the completion of the transaction, the insider owned 207,746 shares of the company’s stock, valued at approximately $5,478,262.02. This trade represents a 1.28% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Christopher Bradley sold 2,572 shares of Alumis stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $26.37, for a total transaction of $67,823.64. Following the transaction, the insider owned 48,533 shares in the company, valued at approximately $1,279,815.21. This trade represents a 5.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders sold 19,953 shares of company stock worth $534,311. Company insiders own 33.70% of the company’s stock.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.